Travel vaccines—priorities determined by incidence and impact

Author:

Steffen Robert1234,Chen Lin H56,Leggat Peter A78910

Affiliation:

1. Epidemiology , Biostatistics and Prevention Institute, Department of Public and Global Health, Division of Infectious Diseases, World Health Organization Collaborating Centre for Travelers’ Health, , Zurich 8001 , Switzerland

2. University of Zurich , Biostatistics and Prevention Institute, Department of Public and Global Health, Division of Infectious Diseases, World Health Organization Collaborating Centre for Travelers’ Health, , Zurich 8001 , Switzerland

3. Division of Epidemiology , Human Genetics & Environmental Sciences, , Houston, TX 77030 , USA

4. University of Texas School of Public Health , Human Genetics & Environmental Sciences, , Houston, TX 77030 , USA

5. Division of Infectious Diseases and Travel Medicine, Mount Auburn Hospital , Cambridge, MA 02138 , USA

6. Faculty of Medicine, Harvard Medical School , Boston, MA 02115 , USA

7. College of Public Health , Medical and Veterinary Sciences, , Townsville, Queensland 4810 , Australia

8. James Cook University , Medical and Veterinary Sciences, , Townsville, Queensland 4810 , Australia

9. School of Public Health , Faculty of Health Sciences, , Johannesburg 2193 , South Africa

10. University of the Witwatersrand , Faculty of Health Sciences, , Johannesburg 2193 , South Africa

Abstract

Abstract Background Infectious disease epidemiology is continuously shifting. While travel has been disrupted by the COVID-19 pandemic and travel-related epidemiological research experienced a pause, further shifts in vaccine-preventable diseases (VPDs) relevant for travellers have occurred. Methods We conducted a literature search on the epidemiology of travel-related VPD and synthesized data for each disease with a focus on symptomatic cases and on the impact of the respective infection among travellers, considering the hospitalization rate, disease sequela and case fatality rate. We present new data and revised best estimates on the burden of VPD relevant for decisions on priorities in travel vaccines. Results COVID-19 has emerged to be a top travel-related risk and influenza remains high in the ranking with an estimated incidence at 1% per month of travel. Dengue is another commonly encountered infection among international travellers with estimated monthly incidence of 0.5–0.8% among non-immune exposed travellers; the hospitalized proportion was 10 and 22%, respectively, according to two recent publications. With recent yellow fever outbreaks particularly in Brazil, its estimated monthly incidence has risen to >0.1%. Meanwhile, improvements in hygiene and sanitation have led to some decrease in foodborne illnesses; however, hepatitis A monthly incidence remains substantial in most developing regions (0.001–0.01%) and typhoid remains particularly high in South Asia (>0.01%). Mpox, a newly emerged disease that demonstrated worldwide spread through mass gathering and travel, cannot be quantified regarding its travel-related risk. Conclusion The data summarized may provide a tool for travel health professionals to prioritize preventive strategies for their clients against VPD. Updated assessments on incidence and impact are ever more important since new vaccines with travel indications (e.g. dengue) have been licensed or are undergoing regulatory review.

Publisher

Oxford University Press (OUP)

Subject

General Medicine

Cited by 10 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3